Education
About Us
Working with TipRanks
Follow Us
Sutro Biopharma Inc (STRO)
NASDAQ:STRO
STRO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.72 - $5.88
Previous CloseN/A
Volume326.60K
Average Volume (3M)1.72M
Market Cap
$61.75M
Enterprise Value$92.45M
Total Cash (Recent Filing)-$47.52M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.15
Next Earnings
May 19, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.01
Shares Outstanding83,775,340
10 Day Avg. Volume2,002,506
30 Day Avg. Volume1,717,291
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.04
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.49
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
$3.17Price Target Upside387.69% Upside
Rating ConsensusHold
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Financial StrengthSutro Biopharma has a solid cash position of $316.9 million, which is seen as a financial strength.
Partnership PotentialSutro Biopharma is considered an ideal partner for big pharmaceutical companies, based on its potential to expand the addressable population in certain cancer treatments.
Pipeline DevelopmentManagement is focusing on advancing their next-generation ADC pipeline, which has potential best-in-class prospects.
Bears Say
Operational RestructuringA reduction in workforce by approximately 50% and changes to the executive leadership team have been announced, reflecting operational restructuring.
Program DiscontinuationThe company announced a deprioritization of the luvelta clinical program, which was a primary driver for the previous investment thesis.
Share PerformanceShares are down -35% YTD as investors view the lack of catalysts and limited positive differentiation for Luvelta as key headwinds.
---
Ownership Overview
9.03% Insiders
10.60% Mutual Funds
33.92% Other Institutional Investors
36.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
STRO FAQ
What was Sutro Biopharma Inc’s price range in the past 12 months?
Sutro Biopharma Inc lowest stock price was $0.72 and its highest was $5.88 in the past 12 months.
What is Sutro Biopharma Inc’s market cap?
Sutro Biopharma Inc’s market cap is $61.75M.
When is Sutro Biopharma Inc’s upcoming earnings report date?
Sutro Biopharma Inc’s upcoming earnings report date is May 19, 2025 which is in 47 days.
How were Sutro Biopharma Inc’s earnings last quarter?
Sutro Biopharma Inc released its earnings results on Mar 13, 2025. The company reported -$0.83 earnings per share for the quarter, the consensus estimate of -$0.83 by $0.
Is Sutro Biopharma Inc overvalued?
According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued.
Does Sutro Biopharma Inc pay dividends?
Sutro Biopharma Inc does not currently pay dividends.
What is Sutro Biopharma Inc’s EPS estimate?
Sutro Biopharma Inc’s EPS estimate is -0.64.
How many shares outstanding does Sutro Biopharma Inc have?
Sutro Biopharma Inc has 83,775,340 shares outstanding.
What happened to Sutro Biopharma Inc’s price movement after its last earnings report?
Sutro Biopharma Inc reported an EPS of -$0.83 in its last earnings report, expectations of -$0.83. Following the earnings report the stock price went down -35.2%.
Which hedge fund is a major shareholder of Sutro Biopharma Inc?
Currently, no hedge funds are holding shares in STRO
---
Sutro Biopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.17 (387.69% Upside)
$3.17 (387.69% Upside)
Blogger Sentiment
Bullish
STRO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 422.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.49%
12-Months-Change
Fundamentals
Return on Equity
-234.19%
Trailing 12-Months
Asset Growth
-17.74%
Trailing 12-Months
Company Description
Sutro Biopharma Inc
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
---
STRO Earnings Call
Q4 2025
0:00 / 0:00
---
STRO Stock 12 Month Forecast
Average Price Target
$3.17
▲(387.69% Upside)
Technical Analysis
Cyclacel Pharmaceuticals
―
Inovio Pharmaceuticals
―
Cue Biopharma
―
Applied Therapeutics
―
Unicycive Therapeutics
―
Best Analysts Covering STRO
1 Year
1 Year Success Rate
0/14 ratings generated profit
1 Year Average Return
-52.36%
reiterated a buy rating 19 days ago
Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -52.36% per trade.
---